Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT719 in Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
NCT07021209Phase 1Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GT719 in neurological autoimmune disease, sponsored by Grit Biotechnology. Primary endpoint: Incidence and severity of adverse events at 24 months. Started Jan 2025; status: recruiting.
02
Drugs
GT719
03
Conditions
neurological autoimmune disease
Beyond the preview
Go deeper on NCT07021209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021209.